Combination Chemotherapy with Continuous l-Asparaginase, Lomustine, and Prednisone for Relapsed Canine Lymphoma
作者： C.F. Saba , S.D. Hafeman , D.M. Vail , D.H. Thamm
DOI: 10.1111/J.1939-1676.2009.0357.X
关键词: Remission duration 、 Combination chemotherapy 、 Canine Lymphoma 、 Prednisone 、 Medicine 、 Response rate (survey) 、 Lomustine 、 Internal medicine 、 Gastroenterology 、 L asparaginase 、 Surgery 、 Toxicity
摘要: Results: The overall response rate (ORR) for dogs treated with this protocol was 77%, 65% achieving a complete (CR). median time to progression (TTP) 70 days. Based on loose comparison, these findings are not significantly different from our previously reported historical control. actual CCNU dosage administered did affect or remission duration. Conclusions/Clinical Importance: These support previous data concluding that the LAP is viable rescue treatment option LSA. However, results study suggest continued use of L-asparaginase each lomustine does increase duration and toxicity appears greater.
cabdirect.org
researchgate.net 
sci-hub.se 参考文章(17)
Emil Frei, Robert C. Bast, Donald W. Kufe, James F. Holland, Principles of Medical Oncology BC Decker. ,(2003)
David M. Vail, Corey F. Saba, Douglas H. Thamm, Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Journal of Veterinary Internal Medicine. ,vol. 21, pp. 127- 132 ,(2007) , 10.1892/0891-6640(2007)21[127:CCWLLA]2.0.CO;2
Antony S. Moore, Susan M. Cotter, William M. Rand, Carrie A. Wood, Laurel E. Williams, Cheryl A. London, Angela E. Frimberger, Deborah A. L'Heureux, Evaluation of a Discontinuous Treatment Protocol (VELCAP‐S) for Canine Lymphoma Journal of Veterinary Internal Medicine. ,vol. 15, pp. 348- 354 ,(2001) , 10.1111/J.1939-1676.2001.TB02328.X
Philip J. Bergman, Gregory K. Ogilvie, Barbara E. Powers, Monoclonal Antibody C219 Immunohistochemistry Against P‐Glycoprotein: Sequential Analysis and Predictive Ability in Dogs With Lymphoma Journal of Veterinary Internal Medicine. ,vol. 10, pp. 354- 359 ,(1996) , 10.1111/J.1939-1676.1996.TB02080.X
A.B. Flory, K.M. Rassnick, R. Al-Sarraf, D.B. Bailey, C.E. Balkman, M.A. Kiselow, K. Autio, Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine. ,vol. 22, pp. 164- 171 ,(2008) , 10.1111/J.1939-1676.2007.0005.X
Jihjong J. Lee, Christine S. Hughes, Robert L. Fine, Rodney L. Page, P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance Cancer. ,vol. 77, pp. 1892- 1898 ,(1996) , 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U
Kenneth M. Rassnick, Glenna E. Mauldin, Renee Al-Sarraf, G. Neal Mauldin, Antony S. Moore, Samantha C. Mooney, MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000) Journal of Veterinary Internal Medicine. ,vol. 16, pp. 576- 580 ,(2002) , 10.1892/0891-6640(2002)016<0576:MCFTOR>2.3.CO;2
Angela E. Frimberger, Deborah A. L'Heureux, Carrie A. Wood, Laurel E. Williams, Cheryl A. London, Antony S. Moore, Susan M. Cotter, Lomustine (CCNU) for the Treatment of Resistant Lymphoma in Dogs Journal of Veterinary Internal Medicine. ,vol. 13, pp. 395- 398 ,(1999) , 10.1892/0891-6640(1999)013<0395:LFTTOR>2.3.CO;2
Kenneth M. Rassnick, Antony S. Moore, Laurel E. Williams, Cheryl A. London, Peter P. Kintzer, Stephen J. Engler, Susan M. Cotter, Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine. ,vol. 13, pp. 601- 605 ,(1999) , 10.1111/J.1939-1676.1999.TB02217.X
Antony S. Moore, Cynthia R. Leveille, Keith A. Reimann, Hsing Shu, Irwin M. Arias, The Expression of P-Glycoprotein in Canine Lymphoma and Its Association with Multidrug Resistance Cancer Investigation. ,vol. 13, pp. 475- 479 ,(1995) , 10.3109/07357909509024910